Company intelligence / Profile preview

Periotherapia

Suita, Osaka, Japan

Ownership: Private
Employees: ~12
Development stage: Other

Overview

Periotherapia has developed neutralizing monoclonal antibodies targeting splicing variants of pathological periostin, showing promising preclinical safety (selective targeting avoids physiological periostin inhibition) and is beginning Phase 1 clinical trials for metastatic and recurrent HER2-negative breast cancer. Efficacy in combination with paclitaxel is under evaluation. Supported by AMED funding and partnership with Eisai.

Therapeutic areas: Oncology
Modalities: Monoclonal antibody
Industry: Biotech

Drug pipeline

1 asset

PT0101

Unknown

Partnerships

Eisai

Beyond the preview

Go deeper on Periotherapia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Periotherapia.

Explore the full profile